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Acute hypercalcemic hypertension in man: Role of hemodynamics,
catecholamines, and renin. The effect of acute hypercalcemia on blood
pressure, blood volume, hemodynamic parameters, plasma norepineph-
rifle, epinephrine, dopamine, renin, and aldosterone concentrations was
investigated. After 1 hour of equilibration, 10 patients received an
infusion of calcium gluconate in 5% dextrose (calcium 15 mg/kg of body
wt in 3 hours). The calcium infusion increased the mean serum calcium
from 8.7 to 13.0 mg/dl, the systolic blood pressure from 144 10 to 184
(5EM) 12 mm Hg (P < 0.001), the diastolic pressure from 78 4 to 93
5 mm Hg (P < 0.01). The plasma volume was decreased by 9% (P <
0.001), whereas the hematocrit was increased (P < 0.05). Heart rate and
cardiac output remained unchanged. Total peripheral resistance was
increased from 1643 223 to 2256 387 dynesec/cm5 (P < 0.05). The
plasma epinephrine concentration rose from 4.5 0.7 to 6.9 1.2 ng/dl(P < 0.01). The plasma norepinephrine concentration was unchanged
after 2 hours and increased only slightly after 3 hours of calcium
infusion. Plasma renin, aldosterone, and dopamine concentrations were
not significantly changed. These findings demonstrate that acute hyper-
calcemic hypertension is mediated by an increase in peripheral vascular
resistance. Hypercalcemic hypertension may be induced by a direct
effect of calcium on blood vessels; calcium-mediated increase in adrenal
epinephrine release may play a mild contributory role, and plasma
volume contraction, an inhibitory role.
Hypertension hypercalcemique aiguë chez I'homme: Role des facteurs
hemodynamiques, des catécholamines, et de Ia refine plasmatiques.
L'effet de l'hypercalcémie aigue sur Ia pression artérielle, le volume
sanguin, les paramètres hCmodynamiques, Ia norepinéphrine, l'épi-
nephrine, Ia dopamine, Ia rénine, et l'aldostérone plasmatiques a été
étudié. Après une heure d'équilibration, 10 sujets ont recu une perfu-
sion de gluconate de calcium dans du dextrose 5% (calcium, 15 mg/kg
de poids en 3 heures). La perfusion de calcium a augmentC Ia concentra-
tion sérique moyenne de calcium de 8,7 a 13,0 mg/dl, Ia pression
artCrielle systolique de 144 10 a 184 (sEM) 12mm Hg (P < 0,001),
Ia pression diastolique de 78 4a 93 5mm Hg (P < 0,01). Le volume
plasmatique a diminué de 9% (P < 0,001) alors que l'hématocrite a
augmenté (P < 0,05). La fréquence cardiaque et Ic debit cardiaque sont
restCs inchangCs. Les resistances totales pCripheriques ont augmente de
1643 223 a 2256 387 dynesec/cm5 (P < 0,05). La concentration
plasmatique de norepinephrine n'était pas modifiée aprés 2 heures et
n'a que peu augmentC après trois heures de perfusion de calcium. Les
concentrations plasmatiques de rénine, d'aldostérone et de dopamine
n'ont pas ete significativement modifiées. Ces constatations montrent
que l'hypertension aiguC hypercalcémique a pour mCdiateur une aug-
mentation des resistances vasculaires périphériques. L' hypertension
hypercalcémique peut étre déterminée par un effet direct de calcium sur
les vaisseaux; l'augmentation de Ia liberation d'epinephrine par les
surrénales, qui a le calcium pour médiateur, peutjouer un role adjuvant
faible et Ia contraction du volume plasmatique un rOle inhibiteur.
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Calcium is an important factor in the regulation of blood
pressure. It plays a central role in the coupling between
excitation and contraction of striated and vascular smooth
muscle cells [1]. Moreover, variations in the concentration of
calcium in the blood may be accompanied by parallel changes in
blood pressure. A rapid reduction of serum calcium concentra-
tion induces hypotension in man [2, 31 and in the experimental
animal [4]. Conversely, both acute [5, 6] or chronic forms of
hypercalcemia [7—12] may be associated with hypertension. The
mechanism by which excess calcium induces hypertension is
still unclear. Theoretically, hypercalcemia could influence
blood pressure by a direct action on the vascular muscle cells;
or its cardiovascular effect could be mediated by other blood-
pressure-regulating factors such as the renin-angiotensin-aldos-
terone axis, the sympathetic nervous system, and circulatory
volume.
Plasma renin levels during acute hypercalcemia in man are
unchanged or slightly decreased [6, 11, 12]. Only few data are
available on the hemodynamic characteristics of hypercalcemic
hypertension [13, 141. Moreover, plasma and urinary catechol-
amines and blood volume have not been evaluated in this
condition. Therefore, the present study was undertaken to
investigate the role of plasma renin, aldosterone, and catechol-
amines levels, plasma and blood volume, and important hemo-
dynamic parameters in the genesis of acute hypercalcemic
hypertension in man.
Methods
Studies with calcium infusion. Because of our previous
demonstration of pressor responses to acute hypercalcemia in
subjects with or without various degrees of renal failure [6], we
again asked subjects with normal or mildly impaired kidney
function to participate in a study. During 1.5 years of recruit-
ment in the outpatient and inpatient departments of our hospi-
tal, ten subjects, aged 19 to 71 years, volunteered and gave
informed consent to undergo the investigations described be-
low. They were six patients with normal kidney function (serum
creatinine, < 1.3 mg/dl; 51Cr-EDTA constant infusion clearance
[15], > 95 mlIminl.73 m2) and four with slightly impaired
kidney function (serum creatinine, 2.2 to 2.8 mg/dl; 5tCr-EDTA
constant infusion clearance, 24 to 36 ml/min1.73 m2). Diag-
noses were chronic glomerulonephritis in four patients (biopsy-
proven in three patients), and chronic interstitial nephritis (N =
1), pyelonephritis (N = 1), polycystic kidney disease (N = 1),
unilateral renal cysts (N = 1) and unilateral renal hypoplasia (N
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Fig. I. Serum calcium and blood pressure before and during i.v.
calcium infusion. Asterisks denote a significant difference from control
conditions: < 0.05; ** < 0.01; *** < 0.001.
= 1). An additional patient was evaluated following an episode
of hematuria but symptoms had already disappeared and no
cause was found. Blood pressure was normal ( 140/90 mm Hg)
in eight patients and mildly elevated in two (diastolic 94 and 95
mm Hg, respectively). There was no history or evidence of
stroke, heart failure, heart block, major arrhythmias, other
cardiovascular complications, or extrarenal organ disease. Nei-
ther of the two female patients was on oral contraceptive drugs.
Six patients agreed to participate in the entire procedure; the
remaining four gave the consent for most of the procedure,
except for the pulmonary artery catheterization and the mea-
surement of cardiac output.
The study started at 8 A.M. The patients rested in the supine
position. A microcatheter (Pulmocath) was inserted percutane-
ously, under local anesthesia, into an antecubital vein and
floated under pressure monitoring to the pulmonary artery. A
second catheter was introduced percutaneously into a brachial
artery, for direct monitoring of arterial pressure. Both catheters
served to collect blood samples for the assessment of cardiac
output. In addition, an i.v. cannula was inserted in each arm;
one was used to collect blood samples for various determina-
tions, and the cannula on the contralateral arm was used for
infusions. Following these preparatory steps, an i.v. infusion of
5% dextrose in water was started and maintained at a minimal
rate (50 ml/hr) for 1 hour of equilibration. At the end of this
equilibration period, basal measurements were obtained, and
the dextrose infusion was replaced by an infusion of calcium
gluconate in 5% dextrose solution. A total of 15 mg of calcium
per kilogram of body weight, dissolved in 500 ml of dextrose
solution, was infused for 3 hours. Heart rate and intraarterial
pressure were monitored every 10 to 15 mm throughout the
entire procedure. Blood samples for determination of plasma
calcium (by autoanalyzer), sodium, potassium (by flame pho-
tometer), phosphate (by colorimeter), protein (by the Biuret
method), renin activity, aldosterone, norepinephrine, epineph-
rifle, and dopamine levels were collected, and cardiac output
(six patients) was measured immediately before and 2 and 3
hours after starting the calcium infusion. Blood and plasma
volumes were determined by a radioisotope dilution technique
using '311-albumin [16] before and at the end (3 hours) of the
calcium infusion.
Studies with dextrose infusion. To evaluate possible calcium-
independent influences of the infusion procedure on blood*Systolic pressure, pulse rate, plasma volume, and endocrine parame-
• Diastolic ters, three additional patients were studied. Their ages ranged
between 58 and 73 years, and their serum creatinine concentra-
tions, between 1.1 and 2.3 mgldl (mean 1.7 0.3 mg/dl).
Following the 1-hour equilibration period (as above), these
patients received an i.v. infusion of 500 ml of 5% dextrose
without calcium; all measurements specified above were ob-
tained except for cardiac output. Informed consent was ob-
tained. as in the former group of patients.
Special analytical procedures. Plasma renin activity and
aldosterone were determined by radioimmunoassay [17, 18],
and plasma norepinephrine, epinephrine and dopamine were
determined by radioenzymatic assay [19], as reported previous-
ly from our laboratory [16, 20]. Intraarterial pressure was
determined with a Statham P23 Db strain gauge transducer and
registered on a Hellige three-channel ink recorder.
Cardiac output was determined by the Fick principle using
oxygen saturation. Oxygen consumption was estimated with
the tables of Fleisch [21]. Total peripheral resistance was
calculated from cardiac output and intraarterial pressure.
Analysis of variance and (if a statistical significance was
present) two-tailed Student's t test for paired data were used for
the statistical comparison of values before and during the
experimental procedure.
Results
Studies with calcium infusion. Calcium infusion increased
serum calcium from 8.7 (sEM) 0.2 to 13.0 0.5 mg/dl (P <
0.001); systolic blood pressure, from 144 10 to 184 12 mm
Hg (P <0.001); and diastolic blood pressure, from 78 4 to 93
5 mm Hg (P < 0.01) (Fig. 1). The hypertensive response was
especially marked for systolic blood pressure, which was
increased by more than 20 mm Hg in each patient. Diastolic and
mean blood pressures were also consistently increased during
calcium infusion. Pressor responses were comparable between
subjects with normal or mildly impaired renal function ( mean
blood pressure, +27 (sEM) 8 vs. +21 4%), and no
consistent difference was noted between subjects whose basal
preinfusion blood pressure was normal ( diastolic blood pres-
sure, + 15 4 mm Hg) or slightly increased (z diastolic blood
pressure + 5 and + 20 mm Hg, respectively). Figure 2 illustrates
the mean changes in blood pressure as related to the alterations
in serum calcium. The increase in blood pressure became
significant when serum calcium was increased by 1 to 2 mg/dl (P
<0.05).
Serum phosphorus was also increased during calcium infu-
sion (from 2.6 0.3 to 4.2 0.3 mg!dl, P < 0.001). Plasma
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sodium (138 1 vs. 136 2 mEq/liter) and potassium (3.8
0.2 vs. 3.9 0.1 mEq/liter) remained unchanged during calcium
infusion.
During calcium infusion, blood volume decreased from 86.6
1.8 to 81.5 2.5 mllkg of lean body mass (LBM) (P < 0.05)
and plasma volume from 54.4 2.5 to 49.5 2.8 mi/kg of LBM
(P <0.001) (Fig. 3). Mean hematocrit was increased from 37.2
2.4 to 39.4 2.8% (P < 0.05), and total serum protein rose
from 6.3 0.2 to 6.7 0.3 g/dl (not significant). Heart rate (69
3 vs. 65 3 beats/mm) and cardiac output (5.0 0.5 vs. 4.8
0.5 liter/mm) were not significantly changed, whereas total
peripheral resistance was increased from 1643 223 to 2256
387 dynesec-cm5 (P < 0.05).
Plasma epinephrine concentration increased progressively
during calcium infusion; changes were significant both at 2 and
3 hours of infusion (P < 0.05 and P < 0.01, respectively) (Table
1). Plasma norepinephrine levels were unchanged after 2 hours
of infusion, but a minimal although significant increase (P <
0.05) was noted after 3 hours. Plasma dopamine, renin, and
aldosterone were not significantly altered. Calcium infusion
was not associated with adverse symptoms; only one patient
complained about fatigue 2 to 3 hours after the infusion.
Studies with dextrose infusion. In three subjects who re-
ceived an i.v. infusion of dextrose only, blood pressure was
149/88 12/5 mm Hg before the infusion and remained
unchanged at 2 (143/88 12/7 mm Hg) and 3 hours (143/88
12/7mm Hg) of infusion. Plasma epinephrine (4.4 1.2 vs. 2.7
1.1 vs. 4.2 2.3 ngldl), norepinephrine (31.8 12.7 vs. 30.2
15.5 vs. 34.8 23.7 ng/dl), dopamine, renin activity,
aldosterone, calcium, phosphorus, sodium, potassium, and
protein levels, hematocrit, plasma and blood volume, as well as
pulse rate, remained also unchanged during dextrose infusion.
Discussion
In this study the hemodynamic profile during acute elevation
of serum calcium concentration (+ 4.3 mgldl) was characterized
by increases in blood pressure (P < 0.001) and total peripheral
vascular resistance (P < 0.05), whereas cardiac output and
Table 1. Effect of acute hypercalcemia on plasma catecholamine, renin, and aldosterone levels"
Plasma Plasma Plasma Plasma
.Duration of calcium
infusion, hr
epinephrine norepinephrine dopamine PRA aldosterone
ng/dl ng/dl ngldl ng/ml/hr ng/dl
0 (control) 4.5 0.7 19.8 4.3 11.6 1.2 2.6 0.8 6.1 1.0
2 59 19.2 3.9 12.4 1.5 2.1 0.7 6.9 1.7
3 6.9 1.2" 23.0 4.6" 12.3 1.3 1.9 0.6 7.1 1.9
a Values are the means SEM.
b p < 0.05, compared with values before calcium infusion.
P < 0.01, compared with values before calcium infusion.
94 Marone et a!
::
30-
E
a,
20-
0I
A Systolic
• Mean
.
• Diastolic
.2Cri0—i
>
Th2m
90
805
--i 60
'a0'E'
.E 50
a.
L5
i.8
80
70
60
10
c
H
6
5
'
2800 -
0
OOtol lto2 2to3 3to4
.
Serum calcium, mg/dI
Fig. 2. Relationship between changes in blood
in serum calcium during iv. calcium infusion.
>5
and increments
.9-'a
a.
2400
2000-
1600-
4to5
pressure
*
0 1 2 3
Duration of calcium infusion, hr
Fig. 3. Plasma and blood volume and hemodynamic indices before and
during calcium infusion. Asterisks denote significant difference from
control conditions: * < 0.05; *** < 0.001.
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heart rate were unaltered. A similar observation was made in
anesthetized dogs [22], and also described as a preliminary
observation in one case [13]. It is known that calcium may
increase the contractility of both the heart [14, 231 and the
peripheral blood vessels [24, 25]. In previous studies in man,
acute hypocalcemia was associated with a decreased cardiac
output [26]; whereas calcium infusion was reported to cause an
increased cardiac output [14] and a slowing of heart rate [231.
The latter studies differ from the present protocol in that the
duration of calcium infusion was very short (5 to 6 mm) and the
degree of hypercalcemia milder, and no increase of blood
pressure occurred in one of them [23]. Nevertheless, it appears
possible that acute hypercalcemic hypertension is initiated by a
very short phase with increased cardiac output [14] and rapidly
progresses to a hemodynamic pattern with elevated peripheral
vascular resistance. Moreover, because an increase in blood
pressure induced by peripheral vasoconstriction should normal-
ly be associated with a compensatory decrease in cardiac
output, the lack of the latter adaptive reaction in our patients
may in fact indicate an inappropriately high cardiac output
during acute hypercalcemia.
Calcium is essential for the contraction of striated and
vascular smooth muscle cells. It is possible, therefore, that the
cardiovascular changes that occur during hypercalcemia are at
least partly owing to a direct effect of the cation of the vascular
muscle cells [27]. It is equally possible that hypercalcemia
increases the sensitivity of the cardiovascular system to the
action of vasoconstrictor substances; but laboratory data do not
support such a concept [25, 281.
The release of catecholamines is calcium dependent [291, and
experimental data have suggested that increased calcium ion
activity may augment the release of epinephrine from the
adrenal medulla [30, 31] and of norepinephrine from the sympa-
thetic nerve endings [32, 33]. Therefore, it appears possible that
the increased plasma epinephrine concentrations during hyper-
calcemia in our patients were due to a direct stimulatory effect
of calcium on adrenal medullary discharge. Plasma norepineph-
rime concentrations, which may be an approximate index of
sympathetic nervous activity, remained unchanged after 2
hours of calcium infusion in these patients, but a minor increase
was noted at 3 hours. The latter variation could be spontaneous
or calcium dependent [32, 33]. It appears probable that the
sympathetic system does not play a prime pathogenic role in
acute hypercalcemic hypertension. Increases in plasma epi-
nephrine during calcium infusion did not exceed the upper limit
of the normal range [34]; and due to its high affinity to beta
adrenergic receptors, an augmented release of this catechol-
amine would be expected to stimulate heart rate and cardiac
output. The absence of "hyperkinetic circulatory pattern"
following 2 to 3 hours of calcium infusion in our patients does
not exclude a mild cardiac stimulatory effect of epinephrine, but
its part in the mechanism of acute hypercalcemic hypertension
may be contributory rather than dominant.
Because plasma renin levels were not significantly altered
during calcium infusion, this factor could not account for acute
hypercalcemic hypertension in our patients. Previous studies in
man revealed unchanged [6, 11] or slightly decreased [12] levels
of circulating renin following calcium infusion, as well as
unaltered plasma renin activity during acute hypocalcemia [31.
Plasma aldosterone levels were also stable in our patients and in
those of others [12]. An increase in circulating aldosterone
following calcium infusion was described in patients with
terminal renal failure [35], but in vitro studies revealed only an
indirect relationship between calcium and aldosterone secretion
[36].
The observed decrease in plasma volume (P < 0.001) and
increase in hematocrit (P < 0.05) during acute hypercalcemia in
our patients are consistent with a mild fluid loss from the
vascular compartment, which cannot be explained by blood
sampling. Volume contraction following calcium infusion could
result from an extravascular shift secondary to a high blood
pressure-induced increase in capillary filtration pressure, or
from an augmented renal sodium diuresis [37]. Whatever the
exact underlying mechanisms, it is possible that intravascular
volume contraction may partly counteract the pressor mecha-
nism of acute hypercalcemia in man.
Taken together, these findings suggest that acute hypercalce-
mic hypertension is mediated by an increase in peripheral vas-
cular resistance. This hypertension may be induced by a di-
rect effect of calcium on the cardiovascular system. A calcium-
mediated increase in adrenal epinephrine release may play a
contributory role; and a reduced plasma volume, an inhibitory
role.
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